Cortisone induces insulin resistance in C2C12 myotubes through activation of 11beta-hydroxysteroid dehydrogenase 1 and autocrinal regulation

Cell Biochemistry and Function

Volumn 32, Issue 3, 2014, Pages 249-257

  Park, Seung Yeon ^a   Bae, Ji Hyun ^a   Cho, Young Sik ^a  

^a Keimyung University   (South Korea)

Author keywords

11 hydroxysteroid dehydrogenase 1; Cortisol; Glucose uptake; Insulin resistance; Myotubes

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; CATHEPSIN B; CORTISONE; GLUCOSE; GLYCYRRHETINIC ACID; HYDROCORTISONE; INSULIN; INTERLEUKIN 6; MIFEPRISTONE; PROTEIN KINASE B; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR;

ARTICLE; AUTOCRINAL REGULATION; BIOLOGICAL ACTIVITY; BIOLOGICAL FUNCTIONS; CATALYSIS; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION; GLUCOSE TRANSPORT; HORMONAL REGULATION; HUMAN; INSULIN RESISTANCE; INSULIN TREATMENT; METABOLIC ACTIVATION; MYOBLAST; MYOTUBE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; ANTAGONISTS AND INHIBITORS; AUTOCRINE EFFECT; CELL LINE; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; SKELETAL MUSCLE;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; AUTOCRINE COMMUNICATION; CELL LINE; CORTISONE; GLUCOCORTICOIDS; GLUCOSE; GLYCYRRHETINIC ACID; HUMANS; HYDROCORTISONE; INSULIN; INSULIN RESISTANCE; MIFEPRISTONE; MUSCLE FIBERS, SKELETAL; RECEPTORS, GLUCOCORTICOID;

EID: 84898034294     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.3008     Document Type: Article

References (45)

1. Stewart PM. Tissue-specific Cushing's syndrome, 11beta-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action. Eur J Endocrinol 2003; 149: 163-168.
2. Agarwal AK, Tusie-Luna MT, Monder C, White PC. Expression of 11 beta-hydroxysteroid dehydrogenase using recombinant vaccinia virus. Mol Endocrinol 1990; 4: 1827-1832.
3. Walker EA, Clark AM, Hewison M, Ride JP, Stewart PM. Functional expression, characterization, and purification of the catalytic domain of human 11-beta -hydroxysteroid dehydrogenase type 1. J Biol Chem 2001; 276: 21343-21350.
4. Wyrwoll CS, Holmes MC, Seckl JR. 11beta-Hydroxysteroid dehydrogenases and the brain: from zero to hero, a decade of progress. Front Neuroendocrinol 2011; 32: 265-286.
5. Covar RA, Leung DY, McCormick D, Steelman J, Zeitler P, Spahn JD. Risk factors associated with glucocorticoid-induced adverse effects in children with severe asthma. J Allergy Clin Immunol 2000; 106: 651-659.
6. Wang M. The role of glucocorticoid action in the pathophysiology of the Metabolic Syndrome. Nutr Metab (Lond) 2005; 2: 3.
7. Walker BR. 11beta-hydroxysteroid dehydrogenase type 1 in obesity. Obes Res 2004; 12: 1-3.
8. Xiang J, Ipek M, Suri V, et al. Synthesis and biological evaluation of sulfonamidooxazoles and beta-keto sulfones: selective inhibitors of 11beta-hydroxysteroid dehydrogenase type I. Bioorg Med Chem Lett 2005; 15: 2865-2869.
9. Arampatzis S, Kadereit B, Schuster D, et al. Comparative enzymology of 11beta-hydroxysteroid dehydrogenase type 1 from six species. J Mol Endocrinol 2005; 35: 89-101.
10. Edgerton DS, Basu R, Ramnanan CJ, et al. Effect of 11 beta-hydroxysteroid dehydrogenase-1 inhibition on hepatic glucose metabolism in the conscious dog. Am J Physiol Endocrinol Metab 2010; 298: E1019-1026.
11. Walker EA, Ahmed A, Lavery GG, et al. 11beta-Hydroxysteroid dehydrogenase type 1 regulation by intracellular glucose 6-phosphate provides evidence for a novel link between glucose metabolism and hypothalamo-pituitary-adrenal axis function. J Biol Chem 2007; 282: 27030-27036.
12. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002; 23: 201-229.
13. Wilcox G. Insulin and insulin resistance. Clin Biochem Rev 2005; 26: 19-39.
14. Febbraio MA, Pedersen BK. Muscle-derived interleukin-6: mechanisms for activation and possible biological roles. Faseb J 2002; 16: 1335-1347.
15. Sinacore DR, Gulve EA. The role of skeletal muscle in glucose transport, glucose homeostasis, and insulin resistance: implications for physical therapy. Phys Ther 1993; 73: 878-891.
16. Mariniello B, Ronconi V, Rilli S, et al. Adipose tissue 11beta-hydroxysteroid dehydrogenase type 1 expression in obesity and Cushing's syndrome. Eur J Endocrinol 2006; 155: 435-441.
17. Morgan SA, Sherlock M, Gathercole LL, et al. 11beta-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle. Diabetes 2009; 58: 2506-2515.
18. Aubry EM, Odermatt A. Retinoic acid reduces glucocorticoid sensitivity in C2C12 myotubes by decreasing 11beta-hydroxysteroid dehydrogenase type 1 and glucocorticoid receptor activities. Endocrinology 2009; 150: 2700-2708.
19. Cho YS, Kim CH, Cheon HG. Cell-based assay for screening 11beta-hydroxysteroid dehydrogenase 1 inhibitors. Anal Biochem 2009; 392: 110-116.
20. Carballo-Jane E, Pandit S, Santoro JC, et al. Skeletal muscle: a dual system to measure glucocorticoid-dependent transactivation and transrepression of gene regulation. J Steroid Biochem Mol Biol 2004; 88: 191-201.
21. Bervar A, Zajc I, Sever N, Katunuma N, Sloane BF, Lah TT. Invasiveness of transformed human breast epithelial cell lines is related to cathepsin B and inhibited by cysteine proteinase inhibitors. Biol Chem 2003; 384: 447-455.
22. Wamil M, Seckl JR. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target. Drug Discov Today 2007; 12: 504-520.
23. Stevens RC, Soelberg SD, Near S, Furlong CE. Detection of cortisol in saliva with a flow-filtered, portable surface plasmon resonance biosensor system. Anal Chem 2008; 80: 6747-6751.
24. Barf T, Vallgarda J, Emond R, et al. Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1. J Med Chem 2002; 45: 3813-3815.
25. Xu R, Sang BC, Navre M, Kassel DB. Cell-based assay for screening 11beta-hydroxysteroid dehydrogenase inhibitors using liquid chromatography/tandem mass spectrometry detection. Rapid Commun Mass Spectrom 2006; 20: 1643-1647.
26. Seckl JR, Morton NM, Chapman KE, Walker BR. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase in adipose tissue. Recent Prog Horm Res 2004; 59: 359-393.
27. Biedasek K, Andres J, Mai K, et al. Skeletal muscle 11beta-HSD1 controls glucocorticoid-induced proteolysis and expression of E3 ubiquitin ligases atrogin-1 and MuRF-1. PLoS One 2011; 6: e16674.
28. Assmann A, Ueki K, Winnay JN, Kadowaki T, Kulkarni RN. Glucose effects on beta-cell growth and survival require activation of insulin receptors and insulin receptor substrate 2. Mol Cell Biol 2009; 29: 3219-3228.
29. Bansal P, Wang Q. Insulin as a physiological modulator of glucagon secretion. Am J Physiol Endocrinol Metab 2008; 295: E751-761.
30. Kim J, Temple KA, Jones SA, Meredith KN, Basko JL, Brady MJ. Differential modulation of 3T3-L1 adipogenesis mediated by 11beta-hydroxysteroid dehydrogenase-1 levels. J Biol Chem 2007; 282: 11038-11046.
31. Karin M. New twists in gene regulation by glucocorticoid receptor: is DNA binding dispensable? Cell 1998; 93: 487-490.
32. Honer C, Nam K, Fink C, et al. Glucocorticoid receptor antagonism by cyproterone acetate and RU486. Mol Pharmacol 2003; 63: 1012-1020.
33. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 1998; 334(Pt 2): 297-314.
34. Ebisui C, Tsujinaka T, Morimoto T, et al. Interleukin-6 induces proteolysis by activating intracellular proteases (cathepsins B and L, proteasome) in C2C12 myotubes. Clin Sci (Lond) 1995; 89: 431-439.
35. Mohamed MM, Cavallo-Medved D, Rudy D, Anbalagan A, Moin K, Sloane BF. Interleukin-6 increases expression and secretion of cathepsin B by breast tumor-associated monocytes. Cell Physiol Biochem 2010; 25: 315-324.
36. Chae HJ, Ha KC, Lee GY, et al. Interleukin-6 and cyclic AMP stimulate release of cathepsin B in human osteoblasts. Immunopharmacol Immunotoxicol 2007; 29: 155-172.
37. Schakman O, Kalista S, Bertrand L, et al. Role of Akt/GSK-3beta/beta-catenin transduction pathway in the muscle anti-atrophy action of insulin-like growth factor-I in glucocorticoid-treated rats. Endocrinology 2008; 149: 3900-3908.
38. Ruzzin J, Wagman AS, Jensen J. Glucocorticoid-induced insulin resistance in skeletal muscles: defects in insulin signalling and the effects of a selective glycogen synthase kinase-3 inhibitor. Diabetologia 2005; 48: 2119-2130.
39. Almon RR, Dubois DC, Jin JY, Jusko WJ. Temporal profiling of the transcriptional basis for the development of corticosteroid-induced insulin resistance in rat muscle. J Endocrinol 2005; 184: 219-232.
40. Ferris HA, Kahn CR. New mechanisms of glucocorticoid-induced insulin resistance: make no bones about it. J Clin Invest 2012; 122: 3854-3857.
41. Nedachi T, Kanzaki M. Regulation of glucose transporters by insulin and extracellular glucose in C2C12 myotubes. Am J Physiol Endocrinol Metab 2006; 291: E817-828.
42. Coutinho AE, Gray M, Brownstein DG, et al. 11beta-Hydroxysteroid dehydrogenase type 1, but not type 2, deficiency worsens acute inflammation and experimental arthritis in mice. Endocrinology 2012; 153: 234-240.
43. Sundbom M, Kaiser C, Bjorkstrand E, et al. Inhibition of 11betaHSD1 with the S-phenylethylaminothiazolone BVT116429 increases adiponectin concentrations and improves glucose homeostasis in diabetic KKAy mice. BMC Pharmacol 2008; 8: 3.
44. Andrews RC, Rooyackers O, Walker BR. Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 285-291.
45. Alberts P, Engblom L, Edling N, et al. Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia 2002; 45: 1528-1532.